RankAlpha logo
Back to Rankings

IMMX

Immix BiopharmaC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
The cleanest bull argument is that enrollment completion has turned IMMX from a vague pipeline story into a dated Q3 2026 readout setup, while the year-end cash balance and expected CIRM support reduce immediate financing pressure into that catalyst window [#8-K-2026-03-30] [#10-K-2026-03-25].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +2.1.
What can break
CIRM grant support is milestone-based and subject to compliance and disbursement conditions, so reimbursement timing is not fully in management control [#10-K-2026-03-25].
Momentum
91
Value
41
Sentiment
38
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $9.50 · Bull $15.00 · Bear $4.50
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-29 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $19.79
Why
Momentum91 · Δ7d +2.1
Value41 · Δ7d -0.1
Sentiment38 · Δ7d +4.7
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
91
26% active weight
Current posture
7d trendImproving
Δ7d
+2.1
Δ21d
+21.9
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
38
34% active weight
Current posture
7d trendImproving
Δ7d
+4.7
Δ21d
-3.5
Why this grade

Composite grade C. Momentum 91.0 / Value 41.1 / Sentiment 37.6

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$729.7M
Beta
0.31
Shares Out
71.19M
P/E (TTM) · Derived
-11.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-12.08
Rev YoY
-
EPS YoY
+19.2%
Gross Margin
-
Op Margin
-
Net Debt
-$99.34M
Current Ratio
8.76
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology